Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Yes, for most people Zepbound (tirzepatide) diarrhea is temporary and tends to ease within a few days to a few weeks as the body adapts, though it often returns briefly after each dose increase. Severity varies by dose, hydration, fiber intake, and whether other medications or conditions are contributing, and several factors can make it linger longer than expected. Warning signs like diarrhea lasting more than two weeks, blood in stool, severe abdominal pain, fever, dizziness, or signs of dehydration point to something beyond normal adjustment and need prompt medical attention. There are important details on timing, self-care steps, and when to call your prescriber below.
Because ongoing diarrhea can stem from the medication, an interaction, or an unrelated gut problem, it is worth taking a free, instant, online symptom check to see whether your pattern fits expected side effects or signals a condition that deserves a closer look, so you can decide your next step with more confidence.
Last reviewed for medical accuracy: 09/13/2026
Diarrhea is a common side effect of Zepbound (tirzepatide), but in most people it does improve as your body adapts to the medication and dose. Here’s what you need to know about why Zepbound causes diarrhea, how long it lasts, and when to seek medical advice.
Why does Zepbound cause diarrhea?
Zepbound is a dual GIP/GLP-1 receptor agonist. Its actions in the gut help lower blood sugar and promote weight loss, but they also alter normal digestive processes:
These effects are dose-dependent: higher doses are more likely to trigger diarrhea than lower ones.
How common is diarrhea with Zepbound?
Data from the FDA prescribing information and phase 3 trials (SURPASS) show:
Does diarrhea get better once my body adjusts?
Yes. For many users, the gastrointestinal system adapts over time. Here’s the typical pattern:
Tips to help your body adjust
While waiting for adaptation, you can take simple steps to ease diarrhea and maintain hydration:
• Slow dose escalation
– Follow your prescriber’s titration schedule strictly.
– If diarrhea is severe, talk to your doctor about extending each dose-increase interval.
• Dietary adjustments
– Eat smaller, more frequent meals.
– Focus on low-fat, low-fiber foods until symptoms improve.
– Avoid spicy or greasy foods that can worsen diarrhea.
• Hydration and electrolytes
– Sip water throughout the day.
– Consider an oral rehydration solution if stools are very loose.
• Over-the-counter remedies
– Loperamide (Imodium) can be used for brief bouts of diarrhea (check with your doctor first).
– Probiotics may help rebalance gut flora, though evidence is mixed.
When to seek medical advice
Most Zepbound-related diarrhea is mild and self-limiting. But contact your healthcare provider if you experience:
You might also consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker if you’re unsure whether your symptoms require immediate care.
Additional considerations
• Other GI side effects: Nausea and vomiting often occur alongside diarrhea. The same adaptation principles apply.
• Drug interactions: Some medicines (antibiotics, metformin) can worsen diarrhea; let your provider know all your medications.
• Underlying conditions: If you have IBS, IBD or chronic pancreatitis, discuss Zepbound’s risks with your doctor.
Key takeaways
Always speak to your doctor about any serious or life-threatening symptoms, or before making changes to your medication regimen. If you’re uncertain about what to do next, consider a quick, free, online symptom check, using the doctor approved Ubie Symptom Checker.
(References)
* Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. PMID: 34186022.
* Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ, SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. PMID: 34672967.
* Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID: PMC8826179.
* Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022 Sep 1;21(1):169. doi: 10.1186/s12933-022-01604-7. Epub 2022 Sep 1. PMID: 36050763; PMCID: PMC9438179.
* Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM, SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.
* France NL, Syed YY. Tirzepatide: A Review in Type 2 Diabetes. Drugs. 2024 Feb;84(2):227-238. doi: 10.1007/s40265-023-01992-4. Epub 2024 Feb 23. PMID: 38388874.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. PMID: 39761578.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.